Clive Spiegler

Clive Spiegler currently acts as Senior Director of New Product Planning for UCB Celltech, the United Kingdom-based branch of the global biopharmaceuticals company UCB, S.A., headquartered in Brussels, Belgium. Clive Spiegler is responsible for the company’s strategic marketing and life cycle strategies for early-phase immunology pipeline products, including their anti-IL6 antibody, as well as for assessing in-licensing opportunities.

Clive Spiegler is also a member of the Immunology Therapeutic Area Strategy Team at UCB Celltech. Clive Spiegler possesses nearly two decades in commercial and research and development roles within the pharmaceuticals industry in both the United States and the European Union. Clive Spiegler’s current role within UCB Celltech began in 2010, and is built upon his previous work in the company.

In the past, Clive Spiegler served as Senior Global Brand Director for Cimzia, UCB’s new monoclonal antibody for relieving the symptoms of people with arthritis and related conditions, such as Crohn’s disease. Cimzia was approved by the FDA for the treatment of rheumatoid arthritis and Crohn’s disease, and by the Committee for Medicinal Products for Human Use of the European Medicines Agency for the treatment of rheumatoid arthritis.